Starling Oncology, Inc.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-15.5M | $-19.9M | $-18.8M | $-17.4M | $-16.9M | $-30.0M | $-11.0M | $-2.7M |
| Depreciation & Amortization | $1.5M | $1.5M | $1.6M | $1.7M | $1.3M | $1.3M | $1.2M | $1.1M |
| Depreciation | $745.0K | $715.0K | $808.0K | $914.0K | $601.0K | $541.0K | $460.0K | $393.0K |
| Amortization | $773.0K | $774.0K | $769.0K | $784.0K | $728.0K | $728.0K | $732.0K | $741.0K |
| Stock-Based Compensation | $3.4M | $4.1M | $4.1M | $4.7M | $4.1M | $5.0M | $6.1M | $6.5M |
| Net Cash from Operating Activities | $-15.7M | $-15.9M | $-3.9M | $-8.3M | $-8.7M | $-15.5M | $-14.0M | $-20.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.8M | $610.0K | $861.0K | $930.0K | $937.0K | $1.8M | $2.0M | $1.2M |
| Business Acquisitions | — | — | — | — | — | — | $470.0K | $-813.0K |
| Net Cash from Investing Activities | $18.2M | $19.4M | $11.6M | $7.7M | $24.9M | $18.4M | $-32.6M | $-87.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-2.1M | $-938.0K | $-1.8M | $-756.0K | $-2.6M | $-1.7M | $-847.0K | $105.4M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-17.5M | $-16.5M | $-4.8M | $-9.2M | $-9.6M | $-17.3M | $-16.0M | $-21.6M |